levetiracetam / Generic mfg. - LARVOL DELTA

Navigating classical Hodgkin lymphoma in a patient with DIAPH1 deletion syndrome: Diagnostic and therapeutic challenges in a rare immuno-genetic context (ASH 2025) - P | "He was commenced on full dose OEPA (vincristine, etoposide, prednisolone, doxorubicin) after histopathologic confirmation of cHL, and following 2 cycles his early response assessment PET showed complete metabolic response. Due to concerns about hepatic enzyme induction and mitochondrial toxicity, anti-seizure therapy was changed to levetiracetam and clobazam, as carbamazepine is a potent CYP3A4 inducer that may decrease exposure to drugs like methylprednisolone (Bartoszek et al., 1987)...This is the first report showing feasibility of full dose induction therapy for cHL with intensive supportive care in DIAPH1 deficiency. Nonetheless, ongoing careful individualised dosing, vigilant toxicity monitoring, and multidisciplinary input remain essential."

Clinical • B Cell Lymphoma • Classical Hodgkin Lymphoma • CNS Disorders • Dental Disorders • Developmental Disorders • Diffuse Large B Cell Lymphoma • Epilepsy • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Mental Retardation • Mucositis • Neutropenia • Non-Hodgkin’s Lymphoma • Ophthalmology • Stomatitis • CYP3A4

Efficacy of levetiracetam prophylaxis in blinatumomab-induced neuro-toxicities in acute lymphoblastic leukemia: Retrospective single-arm cohort study (ASH 2025) - "This retrospective single-arm cohort analysis indicates that prophylactic Levetiracetam administration can significantly lower the occurrence of Blinatumomab related neurological toxicities in patients with B-cell Acute Lymphoblastic Leukemia. Reduction, especially in headache, insomnia, and total neurological adverse events, identifies Levetiracetam as a promising neuroprotective drug in Blinatumomab treatment. These conclusions warrant further confirmation by prospective RCTs to define its efficacy as a regular preventive measure."

Retrospective data • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Central Nervous System Leukemia • CNS Disorders • Epilepsy • Hematological Malignancies • Insomnia • Leukemia • Sleep Disorder

Incidence and risk factors for immune effector cell-associated neurotoxicity syndrome in older patients with relapsed or refractory large B-cell lymphoma: A multicenter study (ASH 2025) - "Median number of prior treatments was 2 (range 1–8), and 44 (20%)had prior bendamustine...Axicabtagene ciloleucel (axi-cel) was most frequently used(58%; n=131) followed by lisocabtagene maraleucel (liso-cel) (16%, n=36) and tisagenlecleucel (tisa-cel)(25%, n=57).Median duration of ICANS was 6 days (interquartile range [IQR] 3–11; range 1–303)...ICANS was managed with steroids in 47 (41%)pts, levetiracetam +/- other agents in 46 (40%) pts, biologic agents +/- other drugs in 15 (13%) pts, andsupportive care in 6 (5%) pts.Median follow-up from the 30-day landmark post-infusion was 17.2 months (95% CI 14.2–22.4)... This large study of older pts with RR LBCL demonstrated acceptable risks of ICANS,comparable to that in pivotal registration trials, with a relatively higher rate of grade ≥3 ICANS. The risksof ICANS were similar regardless of patient age, including those aged ≥80 yrs, but different among CARTproducts. Similar to younger pts, high tumor burden disease and poor..."

Clinical • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma

Icans mitigation in high-risk elderly patients treated with CD28 co-stimulatory anti-CD19 CAR-T cells using a standardization protocol – a pilot study (ASH 2025) - "Mitigation Protocolincluded seizure prophylaxis (levetiracetam and thiamine), early, more intensive corticosteroid treatmentadapted by ICANS grade and anakinra for grade ≥3 or refractory ICANS. However, treatment-related complications – particularly infections and non-relapse mortality were notable. These findingssupport further evaluation of mitigation-based, steroid-sparing strategies to optimize outcomes for olderadults undergoing CAR-T therapy."

CAR T-Cell Therapy • Clinical • CNS Disorders • Epilepsy • Infectious Disease

Quality of life and synergistic combinations of antiseizure medication in patients treated with cenobamate in early therapy lines for focal-onset seizures. (PubMed, Epilepsy Behav) - "Our study provides evidence that CNB in early therapy lines for focal-onset seizures is associated with an increased HrQoL. Low-dose clobazam can wok synergistically with CNB. The combination with SV2A modulators showed a positive trend."

HEOR • Journal • CNS Disorders • Epilepsy

Postoperative seizure prophylaxis after craniotomy: a current evidence and ongoing controversy. (PubMed, Ann Med Surg (Lond)) - "Levetiracetam has largely replaced phenytoin in modern practice due to improved tolerability, though neither has shown clear superiority in preventing late seizures. Most data support selective, rather than routine, prophylaxis limited to the immediate postoperative period in high-risk populations. Future work should focus on individualized risk stratification and standardized institutional protocols."

Journal • CNS Disorders • Epilepsy

Bilateral thalamic infarction secondary to internal cerebral vein thrombosis in a postpartum patient: a rare case report. (PubMed, Ann Med Surg (Lond)) - "The patient was managed in the ICU with therapeutic anticoagulation using low-molecular-weight heparin (LMWH), levetiracetam for seizure prophylaxis, and transitioned to warfarin for long-term anticoagulation treatment. This case highlights the importance of early diagnosis and management of cerebral venous thrombosis to prevent complications. A high index of suspicion is needed for CVT in cases of bilateral thalamic infarction specially in patient with risk factors for venous thromboembolism like postpartum state."

Journal • Cardiovascular • CNS Disorders • Epilepsy • Hematological Disorders • Pain • Thrombosis • Venous Thromboembolism

Phosphodiesterase-4 Inhibition: An Experimental Approach to Overcome Drug Resistance in a Rotenone-Corneal 6 Hz Kindling Mouse Model of Drug-Resistant Epilepsy. (PubMed, Mol Neurobiol) - "Standard anti-seizure medications (ASMs) such as pregabalin, levetiracetam, carbamazepine, phenytoin, and lamotrigine were used for resistance validation. Roflumilast as PDE4 inhibitor significantly manage DRE as evidenced by reducing seizure severity, improving cognitive functions and restoring neurochemical alterations. Its ability to modulate oxidative stress and provide neuroprotection in RCK mice underscores its promise as a novel adjunct treatment for DRE."

Journal • Preclinical • CNS Disorders • Epilepsy • Inflammation • CAT

Spike-wave discharges are uncoupled with cognitive outcome in aged Long-Evans rats. (PubMed, Psychopharmacology (Berl)) - "Together these findings provide evidence that the disrupted excitatory/inhibitory balance associated with individual differences in cognitive aging is unrelated to the SWD increase seen in aged rats."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders

Prenatal Exposure to Antiseizure Medications and the Risk of Congenital Anomalies: A Nationwide Population-Based Study in South Korea. (PubMed, Neurology) - "This study revealed that prenatal exposure to valproate increased the risk of congenital anomalies. Although other ASMs, even in polytherapy, did not significantly increase the overall risk of congenital anomalies, carbamazepine, levetiracetam, oxcarbazepine, and topiramate were associated with specific types of congenital anomalies. Given the limited number of cases, these findings warrant further investigation in other populations."

Journal • Retrospective data • CNS Disorders • Epilepsy • Ventriculomegaly

Effect of Anti-Seizure Medications on Interictal Epileptiform Discharges in Focal Epilepsy. (PubMed, Clin EEG Neurosci) - "For those on levetiracetam, there was a significant increase in IED quantity when comparing the high-ASM to the low-ASM epoch (mean 40.6 to 71.4, p < 0.001)...Some populations of IEDs were only seen after ASMs were weaned. These findings suggest that different ASMs may have unique effects on IEDs when weaned."

Journal • CNS Disorders • Epilepsy

BALANCE: B6 Administration for Levetiracetam-Associated Neurobehavioral Changes and Epilepsy (clinicaltrials.gov) - P=N/A | N=50 | Not yet recruiting | Sponsor: Duke University

New trial • Brain Cancer • CNS Disorders • Epilepsy • Solid Tumor

A Successful Rechallenge in a Patient With Oxaliplatin-Induced Tonic-Clonic Seizures Under Anticonvulsant Therapy. (PubMed, Case Rep Oncol Med) - "The patient received levetiracetam after the seizure onset and was successfully retreated with oxaliplatin 6 months later. This case highlights a rare presentation of oxaliplatin-induced seizure occurring in the absence of PRES or other identifiable metabolic, structural, or infectious causes. Notably, successful rechallenge with oxaliplatin was achieved after a prolonged seizure-free interval and under antiepileptic coverage, suggesting that rechallenging may be considered in selected patients following multidisciplinary evaluation."

Journal • CNS Disorders • Colorectal Adenocarcinoma • Colorectal Cancer • Epilepsy • Oncology • Pain • Rectal Adenocarcinoma • Solid Tumor

Elevated thalamic blood flow in self-limited epilepsy with centrotemporal spikes. (PubMed, Epilepsy Res) - "ASM use significantly modulated thalamic blood flow: children taking oxcarbazepine showed the highest CBF, while those on levetiracetam had CBF similar to controls. These findings demonstrate that elevated thalamic blood flow may be intrinsic to SeLECTS pathophysiology, with different ASMs producing distinct neurobiological effects. The differential medication effects may relate to their clinical efficacy and provide neurobiological rationale for treatment selection in this common childhood epilepsy syndrome."

Journal • Anesthesia • CNS Disorders • Epilepsy

Association of Aggression and Anti-seizure Medications in Pediatric Patients: Disproportionality Analysis Using the FDA Adverse Event Reporting System. (PubMed, Eur J Pharmacol) - "Signals of aggression related to different ASMs were identified. Significantly strong signals were observed for perampanel, levetiracetam and brivaracetam. Compared to infants and preschooler, ASMs-associated aggression is more common in school children and teenagers."

Adverse events • Journal • CNS Disorders • Epilepsy • Pediatrics

Aphasic status epilepticus complicating hyperosmolar hyperglycaemic state. (PubMed, Pract Neurol) - "Initial treatment with insulin and levetiracetam led to significant recovery. This case underscores hyperosmolar hyperglycaemic states as a reversible cause of aphasic status epilepticus and highlights the varied neurological presentations of uncontrolled diabetes. We include a review of the literature to contextualise this under-recognised clinical entity."

Journal • Ataxia • CNS Disorders • Diabetes • Epilepsy • Metabolic Disorders • Type 2 Diabetes Mellitus

Interaction between Carbamazepine and Concomitant Levetiracetam Therapy in Patients with Epilepsy. (PubMed, Can J Hosp Pharm) - No abstract available

Journal • CNS Disorders • Epilepsy

Treatment approaches in posthypoxic myoclonus: A narrative review with expert opinion. (PubMed, Epilepsia) - "Treatment remains largely empirical and variable, with benzodiazepines and antiseizure medications (e.g., levetiracetam, valproate, clonazepam, perampanel) being commonly used. Acute PHM is a clinically heterogeneous disorder with significant diagnostic and therapeutic challenges. Future research should focus on refining diagnostic criteria and identifying targeted therapies to improve outcomes in this often-fatal condition."

Journal • Review • Cardiovascular • CNS Disorders • Epilepsy • Movement Disorders

Case Series Assessing the Use of Levetiracetam for Gait Improvement in Primary Lateral Sclerosis. (PubMed, Can J Neurol Sci) - "Patient 2 improved 18% (90 m in 4:29 min to 112 m in 6 min) on 6MWT and 10% (46-41 s) on TUG. Larger prospective trials of levetiracetam for spasticity and gait may be considered in PLS."

Journal • Amyotrophic Lateral Sclerosis • CNS Disorders • Movement Disorders

Prevalence and factors associated with seizures in tuberculous meningitis. (PubMed, Med J Malaysia) - "Seizures are common in TBM and are associated with worse clinical outcomes. Early clinical signs such as altered behaviour and focal deficits may help identify high-risk TBM patients with seizures. Seizures in TBM are associated with worse neurological outcomes. The common antiseizure therapy initiated for treatment include phenytoin, valproate and levetiracetam. Further prospective studies are needed to refine risk stratification and optimize management."

Journal • Observational data • Retrospective data • CNS Disorders • Epilepsy • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

ICANS and seizure-like activity observed after treatment with glofitamab in patient with diffuse large B-cell lymphoma: a case report (SNO 2025) - "The patient is a 78-year-old female with aggressive DLBCL which was poorly responsive to several lines of therapy, including 4 cycles of mini R-CHOP, 4 cycles of Pola-BR, and gemcitabine oxaliplatin. Glofitamab, with obinutuzumab pretreatment, was started as a disease-holding bridging therapy while insurance approval for CAR T-cell therapy was in process...Patient was treated with IV steroids (initially IV dexamethasone 10 mg q6 hours followed by IV methylprednisolone 1g daily then IV dexamethasone taper), levetiracetam (1000 mg q12 hours IV) and, briefly, with anakinra (100 mg q6 hours) with resolution of nystagmus, seizure-like activity and altered mental status. This case is an example of ICANS presenting with seizure-like activity and altered mental status in a patient treated with glofitamab. Additional studies are needed to understand the pathophysiology and management of glofitamab-induced ICANS."

Case report • Clinical • B Cell Lymphoma • CNS Disorders • Diffuse Large B Cell Lymphoma • Epilepsy • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Metabolic Disorders • Movement Disorders • Non-Hodgkin’s Lymphoma • Ophthalmology • CD20

A Multifaceted Case of CASPR2 Antibody-Associated Autoimmune Encephalitis Presenting with Gait Disturbances, Visual Abnormalities, and Temporal Lobe Epilepsy (AES 2025) - "Levetiracetam was started but later switched to lacosamide due to adverse mood effects...The patient had significant improvement of dizziness, gait disturbance and cognition following 5 days of high-dose intravenous methylprednisolone followed by oral prednisone taper...Steroid therapy was re-escalated, and the patient was scheduled for initiation of rituximab. This case underscores the diagnostic challenges posed by CASPR2 antibody-associated autoimmune encephalitis, particularly when presenting with non-specific symptoms of orthostatic hypotension and suspected peripheral neuropathy in the context of unrevealing imaging. Early clinical suspicion and initiation of immunotherapy are critical to optimizing neurologic and functional outcomes."

Clinical • Alzheimer's Disease • Cardiovascular • CNS Disorders • Cognitive Disorders • Coronary Artery Disease • Epilepsy • Hypertension • Hypotension • Immunology • Thrombosis • CNTN

Incidence of seizures and practice patterns of antiseizure medications in primary supratentorial brain tumors: results from a prospective study (SNO 2025) - P3 | "Levetiracetam was the most common ASM used in 90% of patients, commonly started in combination with other ASMs in 35% during referral to our center... Seizure control should be a major clinical goal in the management of brain tumors, and the majority are seen during the presentation and initial 2 years of diagnosis. The optimal duration of ASM use needs to be defined with an ongoing phase 3 randomized controlled trial (LIBRA study, NCT06442748)."

Clinical • Brain Cancer • CNS Disorders • Epilepsy • Glioblastoma • Glioma • Meningioma • Oncology • Solid Tumor

Levetiracetam therapeutically targets GABAergic synapses in diffuse midline glioma (SNO 2025) - "Increasing GABA signaling with the benzodiazepine lorazepam increases glioma proliferation and reduces survival in xenograft models of DMG but not IDH-WT HGG. Retrospective real-world clinical data demonstrate longer overall survival for children with DMG who were taking levetiracetam, which was not evident in pediatric hemispheric HGG. These findings uncover growth-promoting GABAergic synaptic communication between GABAergic neurons and DMG cells, underscoring a tumor subtype-specific mechanism of brain cancer neurophysiology with potentially important implications for commonly used drugs in this disease context, which should be further studied in future prospective clinical studies."

Brain Cancer • CNS Disorders • Diffuse Midline Glioma • Epilepsy • Glioblastoma • Glioma • High Grade Glioma • Solid Tumor

Comparative efficacy and safety of Levetiracetam versus valproic acid in migraine prophylaxis: A systematic review and meta-analysis (EHF-EHC 2025) - "However, the two drugs remained broadly comparable with respect to headache duration, severity, functional disability, and tolerability. However, larger, high-quality trials are needed to further explore the comparative efficacy and safety profiles of levetiracetam and valproic acid, so as to better inform individualized treatment strategies in migraine prophylaxis."

Retrospective data • Review • CNS Disorders • Migraine • Pain